Do you offer consolidative thoracic radiotherapy to patients with extensive stage SCLC who have a complete response to chemotherapy?

The CREST trial did not meet primary goal of improving one year survival, but it did improve 2 year OS. Looking at subset, achieving CR to chemo was an indicator of a group that "did not benefit". So the rest of the question (what volume, what dose etc) becomes irrelevant.

Overall, my clinical practice mirrors that of Dr. @Dr. First Last's answer based on subset analysis of the CREST trial suggesting that the patients who benefited the most were those with only a partial response in the chest, these are not full independent publications but rather information presente...